Combining Capabilities to Serve More Patients with Rare Diseases

This press release contains forward-looking statements within the meaning of the federal securities law. Such statements are based upon current plans, estimates and expectations that are subject to various risks and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Words such as “anticipate,” “expect,” “project,” “intend,” “believe,” “may,” “will,” “should,” “plan,” “could,” “target,” “contemplate,” “estimate,” “predict,” “potential” and words and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking statements. All statements, other than historical facts, including statements regarding the expected timing of the closing of the merger; the ability of the parties to complete the merger considering the various closing conditions; the expected benefits of the merger, such as efficiencies, cost savings, tax benefits, enhanced revenues and cash flow, growth potential, market profile and financial strength; the competitive ability and position of the combined company; and any assumptions underlying any of the foregoing, are forward-looking statements. Important factors that could cause actual results to differ materially from Idera’s and BioCryst’s plans, estimates or expectations could include, but are not limited to: (i) Idera or BioCryst may be unable to obtain stockholder approval as required for the merger; (ii) conditions to the closing of the merger may not be satisfied; (iii) the merger may involve unexpected costs, liabilities or delays; (iv) the effect of the announcement of the merger on the ability of Idera or BioCryst to retain and hire key personnel and maintain relationships with customers, suppliers and others with whom Idera or BioCryst does business, or on Idera’s or BioCryst’s operating results and business generally; (v) Idera’s or BioCryst’s respective businesses may suffer as a result of uncertainty surrounding the merger and disruption of management’s attention due to the merger; (vi) the outcome of any legal proceedings related to the merger; (vii) Idera or BioCryst may be adversely affected by other economic, business, and/or competitive factors; (viii) the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement; (ix) risks that the merger disrupts current plans and operations and the potential difficulties in employee retention as a result of the merger; (x) the risk that Idera or BioCryst may be unable to obtain governmental and regulatory approvals required for the transaction, or that required governmental and regulatory approvals may delay the transaction or result in the imposition of conditions that could reduce the anticipated benefits from the proposed transaction or cause the parties to abandon the proposed transaction; (xi) risks that the anticipated benefits of the merger or other commercial opportunities may otherwise not be fully realized or may take longer to realize than expected; (xii) the impact of legislative, regulatory, competitive and technological changes; (xiii) risks relating to the value of the new holding company shares to be issued in the merger; (xiv) expectations for future clinical trials, the timing and potential outcomes of clinical studies and interactions with regulatory authorities; and (xv) other risks to the consummation of the merger, including the risk that the merger will not be consummated within the expected time period or at all. Additional factors that may affect the future results of Idera and BioCryst are set forth in their respective filings with the SEC, including each of Idera’s and BioCryst’s most recently filed Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC, which are available on the SEC’s website at www.sec.gov. See in particular Item 1A of Idera’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016 under the heading “Risk Factors” and Item 1A of BioCryst’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017 under the heading “Risk Factors.” The risks and uncertainties described above and in Idera’s most recent Annual Report on Form 10-K and BioCryst’s most recent Quarterly Report on Form 10-Q are not exclusive and further information concerning Idera and BioCryst and their respective businesses, including factors that potentially could materially affect their respective businesses, financial condition or operating results, may emerge from time to time. Readers are urged to consider these factors carefully in evaluating these forward-looking statements, and not to place undue reliance on any forward-looking statements. Readers should also carefully review the risk factors described in other documents that Idera and BioCryst file from time to time with the SEC. The forward-looking statements in this press release speak only as of the date of this press release. Except as required by law, Idera and BioCryst assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. Forward Looking Statements 2

In connection with the proposed merger, Idera and BioCryst plan to file with the SEC and mail or otherwise provide to their respective stockholders a joint proxy statement/prospectus regarding the proposed transaction. BEFORE MAKING ANY VOTING DECISION, IDERA’S AND BIOCRYST’S RESPECTIVE STOCKHOLDERS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS IN ITS ENTIRETY WHEN IT BECOMES AVAILABLE AND ANY OTHER DOCUMENTS FILED BY EACH OF IDERA AND BIOCRYST WITH THE SEC IN CONNECTION WITH THE PROPOSED MERGER OR INCORPORATED BY REFERENCE THEREIN BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES TO THE PROPOSED TRANSACTION. Investors and stockholders will be able to obtain a free copy of the joint proxy statement/prospectus and other documents containing important information about Idera and BioCryst, once such documents are filed with the SEC, through the website maintained by the SEC at www.sec.gov. Idera and BioCryst make available free of charge at www.iderapharma.com and www.biocryst.com, respectively (in the “Investors” section), copies of materials they file with, or furnish to, the SEC. Participants in the Solicitation This document does not constitute a solicitation of proxy, an offer to purchase or a solicitation of an offer to sell any securities. Idera, BioCryst and their respective directors, executive officers and certain employees and other persons may be deemed to be participants in the solicitation of proxies from the stockholders of Idera and BioCryst in connection with the proposed merger. Security holders may obtain information regarding the names, affiliations and interests of Idera’s directors and officers in Idera’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016, which was filed with the SEC on March 15, 2017, and its definitive proxy statement for the 2017 annual meeting of stockholders, which was filed with the SEC on April 28, 2017. Security holders may obtain information regarding the names, affiliations and interests of BioCryst’s directors and officers in BioCryst’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016, which was filed with the SEC on February 27, 2017, and its definitive proxy statement for the 2017 annual meeting of stockholders, which was filed with the SEC on April 12, 2017. To the extent the holdings of Idera securities by Idera’s directors and executive officers or the holdings of BioCryst securities by BioCryst’s directors and executive officers have changed since the amounts set forth in Idera’s or BioCryst’s respective proxy statement for its 2017 annual meeting of stockholders, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Additional information regarding the interests of such individuals in the proposed merger will be included in the joint proxy statement/prospectus relating to the proposed merger when it is filed with the SEC. These documents (when available) may be obtained free of charge from the SEC’s website at www.sec.gov, Idera’s website at www.iderapharma.com and BioCryst’s website at www.biocryst.com. Additional Information and Where to Find It 3

A unique player in rare diseases with scale Diversified late-stage pipeline Synergistic potential with best-in-class people, facilities and commercial know-how in rare diseases Experienced development capabilities across organization Active and complementary discovery engines Financial strength Combination Creates Substantial Value 4

Robust Pipeline Complementary Leadership Proven commercial team; launched 1st prophylactic HAE product Extensive clinical development experience Significant experience with 2 distinct engines Expands number of rare disease targets ~$243 million net cash balance* Opportunities to add cash through partnering and other programs Patient-Centric Rare Disease Culture and Approach * Unaudited pro-forma cash balance as of December 31, 2017 Financial Strength Synergistic Discovery Engines 2 Phase 3 orphan-designated programs with compelling data 2 additional Phase 2 rare disease programs 9 total rare disease programs 4 supporting asset programs 5

Phase 3 Programs Create a Financially Strong Foundation to Support a Robust Rare Disease Pipeline 6 BCX7353 Prophylactic HAE IMO-2125 PD-1 Refractory Melanoma in Combination with ipilimumab Once a day oral (capsule) Competitive attack rate reduction 73% Safety & tolerability similar to placebo at most effective dose $2 billion projected global market opportunity Phase 3 ready Novel agent designed to induce abscopal anti-tumor immune response Robust and durable clinical and translational data generated Opportunity to improve immuno-oncology outcomes with CPIs across multiple tumor types Multi billion dollar opportunity, plus data, driving strategic interest in partnering Compelling Data driving 2 Phase 3 programs Strong cash flow opportunities from commercializing and partnering

Merger Upside: Maximizing Value and Market Potential 7 Value Driver Merger Amplifier Commercializing BCX7353 Idera management HAE launch experience Investing in commercial launch and ongoing pipeline development Capital from IMO-2125 out licensing opportunities Expanding market opportunity + diversifying risk BCX7353 and IMO-2125 Phase 3 opportunities in rare disease markets + IMO-2125 in other cancer markets Building rare disease pipeline Leveraging and combining complementary discovery engines

Maximizing Value, Minimizing Risk, Multiplying Opportunity 8 BCX7353 HAE Prophylaxis (Capsule) BCX7353 HAE Acute (Liquid) Gen II kallikrein inhibitors (HAE & Other Indications) BCX9250 BCX9499 (FOP) Small Molecule Rare Disease Discovery Engine IMO-2125 PD-1 Refractory Melanoma IMO-8400 Dermatomyositis IMO-2125 Solid Tumor Monotherapy IDRA-008 Liver Target Oligo Rare Disease Discovery Engine

+ Lead optimization Pre-clinical Ph 1 Ph 2 Ph 3 Filed Approved STRATEGY: Discover and develop novel therapies for life-threatening, rare diseases IMO-2125 – PD-1 Refractory Melanoma in combination with ipilimumab BCX7353 – HAE Prophylaxis (Capsule) IMO-8400 – Dermatomyositis BCX7353 – HAE Acute (Liquid) IMO-2125 – Solid Tumor Monotherapy Second generation kallikrein inhibitors (HAE & Other Indications) IDRA-008 – Liver Target BCX9250 BCX9499 Other rare diseases SUPPORTING ASSETS: Externally funded, potential for significant capital infusions RAPIVAB® (peramivir injection) IMO-9200 – Autoimmune Disease Galidesivir (broad spectrum antiviral) 3GA Candidate – Renal Target licensed to Seqirus, Shionogi and Green Cross licensed to Vivelix licensed to GSK Fibrodysplasia Ossificans Progressiva (FOP) – Orphan-Designation Orphan-Designation Robust Rare-Disease Focused Pipeline 9

+ Oral (capsule) Kallikrein Inhibitor for Hereditary Angioedema One pill, once a day – fulfilling patient needs HAE market expected to exceed $2B in global sales Robust quality of life data BCX7353 Prophylactic HAE IMO-2125 PD-1 Refractory Melanoma in Combination with ipilimumab Subcutaneous TLR 7,8,9 antagonist therapy for dermatomyositis Severely debilitating disease affecting skin and muscle in ~25K patients in the U.S. IMO-8400 Dermatomyositis Oral (liquid) Kallikrein Inhibitor for Hereditary Angioedema Complementary acute therapy to create an HAE portfolio Global acute markets and breakthrough attack therapy BCX7353 Acute HAE Phase 3 Initiating Q1 2018 (orphan designations) Phase 2 Data in 2018 Intratumoral TLR9 Agonist for Rare Cancer Indication – Refractory Melanoma Peak year sales estimate > $500 million Long-term expansion into I/O addressable and unaddressable tumors Portfolio of Late-Stage Programs 10

1st prophylactic treatment of HAE Grew to ~$400M in N.A. annual sales in 5 years Treatment of C. difficile-associated diarrhea (CDAD) Grew to ~$300M in annual sales Multiple global and U.S. rare disease launches Led launch for 5 global brands that drive ~70% of CSL’s current revenue Grew U.S. Hizentra and Privigen sales to >$1B Vincent Milano Chief Executive Officer Lynne Powell Chief Commercial Officer Clayton Fletcher VP, Strategy/ Bus. Development Dan Soland Chief Operating Officer Proven Rare Disease Clinical & Commercial Track Record William Sheridan, MB BS Chief Medical Officer Joanna Horobin, MB ChB Chief Medical Officer 11 >245 HAE patients dosed and studied CMOs clinical development/launch experience: Aranesp®, Enbrel®, Kineret®, Neulasta®, Sensipar® Taxotere® Bactroban®, Relafen®/ Reliflex® Lovenox®, Celectol®, Augmentin®, Timentin®, Temocillin®.

Extensive experience in both discovery approaches within one organization Combining technologies expands ability beyond stand-alone Combination therapy of small molecule and oligo may create more effective and potent treatments for rare diseases Combination Creates Opportunities for Innovative Medicines Structure-Guided Small Molecule Design Nucleic Acid/ Oligonucleotide Chemistry Synergistic Discovery Engines 12

~$243 million net cash balance* Capital for continued clinical development beyond next milestone events Commercial launch planning and preparation Additional $20+ million (non-dilutive) procurement contract anticipated in 2018 Opportunities to generate non-dilutive capital through non-strategic assets/indications Headquarters consolidation to Exton, PA; research center consolidated to Birmingham, AL Expense consolidation over time expected to create cost savings and benefits Solid Capital Position & Meaningful Operational Synergies 13 * Unaudited pro-forma cash balance as of December 31, 2017

Initiate APEX-2 Ph 3 Pivotal Trial in HAE prophylaxis BCX 7353 Q1 Initiate ILLUMINATE 301 Ph 3 Pivotal Trial in PD-1 Refractory Metastatic Melanoma in combination with ipilimumab IMO-2125 Q1 Data available from PIONEER Phase 2 Trial in Dermatomyositis IMO-8400 Q2 Complete enrollment in ILLUMINATE 204 Phase 2 Trial in PD-1 Refractory Metastatic Melanoma IMO-2125 Q2 2018: Significant Near-Term Value-Building Events + BCX 7353 Data from ZENITH-1 Phase 2 Study in Acute HAE STRATEGIC Potential partnering and additional business development activities IMO-2125 ILLUMINATE 204 Phase 2 Trial in PD-1 Refractory Metastatic Melanoma in combination with ipilimumab – update at ASCO 2018 14

Extraordinary drug discovery, development and commercialization so patients can have a better quality of life + Combining Capabilities to Serve More Patients with Rare Diseases 15

A unique player in rare diseases with scale Diversified late-stage pipeline Synergistic potential with best-in-class people, facilities and commercial know-how in rare diseases Experienced development capabilities across organization Active and complementary discovery engines Financial strength Combination Creates Substantial Value 16

Combining Capabilities to Serve More Patients with Rare Diseases +

Terms Stock for stock transaction Each share of BioCryst to be converted into 0.50 shares of new company stock Each share of Idera to be converted into 0.20 shares of new company stock Ownership at Closing BioCryst stockholders to own approximately 51.6% of combined company and Idera stockholders to own approximately 48.4% of combined company, each on a fully-diluted basis Cash Position ~$243 million net cash balance* Opportunities for non-dilutive capital Board of Directors New board comprised of 4 BioCryst directors, 4 Idera directors, and 1 new independent director Robert Ingram, Chairman of the Board of Directors (current BioCryst Chairman) Jon Stonehouse, CEO of BioCryst, to join Board Vincent Milano, CEO of Idera, to join Board CEO, Headquarters, and Research Center Vincent Milano, Chief Executive Officer Headquarters: Exton, PA Research Center: Birmingham, AL Closing Conditions Subject to approval of BioCryst and Idera stockholders Subject to other customary closing conditions Voting Agreement A significant stockholder of each company has agreed to enter into a voting and support agreement and has agreed to vote in favor of the transaction. This stockholder owns ~9% of Idera shares outstanding and ~14% of BioCryst shares outstanding. Transaction Close Expected in second quarter 2018 * Unaudited pro-forma cash balance as of December 31, 2017 Combination Highlights 18

APeX-1: Overall Angioedema Attack Rate per Week, PP Population, Weeks 2-4 and 1-4 19 1.0 0.5 0 62.5mg 125mg 250mg 350mg WEEKS 2-4 % Difference, Active-PBO -7% -73% -46% -58% p-Value 0.715 <0.001 0.006 <0.001 WEEKS 1-4 % Difference, Active-PBO -6% -69% -53% -48% p-Value 0.747 <0.001 <0.001 <0.001 WEEKS 2-4 WEEKS 1-4 Attack Rate: LS Mean Attacks/Week Placebo BCX7353 62.5mg QD BCX7353 125mg QD BCX7353 250mg QD BCX7353 350mg QD

APeX-1: 125 mg Dose Provided Consistent Reductions in Attack Rate 20 1 Least squares mean calculated using an ANCOVA model with qualifying attack rate as covariate Analysis n LS mean1 Attacks per Week Difference vs Placebo Percentage Reduction vs Placebo p-Value vs Placebo BCX7353 125 mg Placebo Confirmed attacks, Weeks 2-4 PP population 13 0.248 0.932 -0.684 73% <0.001 Confirmed attacks, Weeks 2-4 ITT population 14 0.249 0.937 -0.688 73% <0.001 Confirmed attacks, Weeks 1-4 PP population 13 0.278 0.895 -0.617 69% <0.001 Confirmed attacks, Weeks 1-4 ITT population 14 0.270 0.890 -0.619 70% <0.001 Confirmed attacks requiring treatment, Weeks 2-4 PP population 13 0.221 0.807 -0.585 73% <0.001 Confirmed attacks requiring treatment, Weeks 2-4 ITT population 14 0.224 0.771 -0.546 71% 0.002 Confirmed attacks requiring treatment, Weeks 1-4 PP population 13 0.221 0.788 -0.567 72% <0.001 Confirmed attacks requiring treatment, Weeks 1-4 ITT population 14 0.217 0.753 -0.536 71% <0.001

APeX-1: Angioedema Quality of Life (AE-QoL): LS Mean Change from BL at Day 29, PP 21 Difference in adjusted least square means are shown (Active treatment minus Placebo). ANCOVA Model includes terms of treatment and adjusted qualifying attack rate. Reductions (negative changes from BL) represent improvement in quality of life scores. MCID, minimum clinically important difference, -6 points (Weller, K. 2016. Allergy 71(8): 1203-1209.) BCX7353 dose level compared with placebo 0 -10 MCID Total Score Placebo BCX7353 62.5mg QD BCX7353 125mg QD BCX7353 250mg QD BCX7353 350mg QD * ** ** ** ** * * * p<0.05 ** p<0.005 QOL Score Improved -20 -30 -40 Functioning Fatigue/Mood Fears/Shame Nutrition

1 TEAE- treatment-emergent adverse event. 2 GI infection- investigator assessed as unrelated to study drug. Abdominal symptoms similar to several previous non-HAE-attack episodes occurring over past 3 years resulting in severe vomiting and diarrhea. Pt presented to ER and hospitalized for IV fluids and antiemetics as a precaution. No HAE acute attack meds given. Recovered and discharged the following day. Missed 1 day of dosing due to event. 3 Pre-existing liver disorder (improved from baseline, but persisting). Previously reported in 1st interim analysis. 4 n=1 Gastroenteritis with liver disorder (both assessed as related) (elevated ALT 1.9x ULN, GGT 5.4x ULN and ALP 1.6x ULN, with normal AST and bilirubin). Previously reported in 1st interim analysis. 5 n=1 Vomiting/abdominal cramps. Previously reported in 2nd interim analysis. APeX-1: Treatment-Emergent Adverse Event Summary 22 BCX7353 Category 62.5 mg N = 7 125 mg N = 14 250 mg N = 14 350 mg N = 18 Placebo N = 22 Subjects with any TEAE1, n (%) 4 (57) 7 (50) 11 (79) 14 (78) 15 ( 68.2) Subjects with any Serious AE, n (%) 0 0 1 (7)2 0 0 Subjects with Drug-Related Grade 3/4 AE, n (%) 0 0 0 1 (6) 0 Subjects with AE Leading to D/C from Study Drug, n (%) 0 0 0 3 (17) 0 Non-drug-related, n (%) 0 0 0 1 (6)3 0 Drug-related, n (%) 0 0 0 2 (11)4,5 0

APeX-1: Exposure Comparisons of BCX7353 and SC C1INH 23 1 Longhurst, H. et al. N Engl J Med 376, 1131-1140 (2017). Box plots represent median, 25th and 75th percentiles, minimum and maximum values. CSL-830 and BCX7353 data are from distinct clinical trials and no head to head study has been conducted. CSL-830 Phase 3 Study BCX7353 APeX-1 & Phase 1 Study C1INH levels at baseline and after SC dosing with CSL-8301 BCX7353 plasma concentrations at 24 hours post-dose Baseline 40 IU/kg 60 IU/kg 10 100 2 4 8 16 32 CSL Phase 3 COMPACT study C1INH levels in COMPACT study % of normal mean Multiple of EC 50 Baseline 1 (observed) Trough during dosing 1 ( predicted from population PK ) 62.5 mg 125 mg 250 mg 350 mg 125 mg 250 mg 350 mg 500 mg 2 4 8 16 32 BCX7353 Trough Concentrations Phase 1 Study APeX-1 Multiple of EC 50 [geo. mean & SD] Oral daily dose of BCX7353

Predictable PK Supports 175 mg as Second Dose in Phase 3 24 Given the predictable PK of BCX7353, simulations are helpful in selecting an intermediate dose of BCX7353 to study that is between 125 mg and 250 mg. These simulations suggest a relatively small increase in dose above 125 mg should achieve a significant increase in the proportion of subjects achieving trough levels above the therapeutic target. These simulations suggest 175 mg dose should maintain trough drug levels > 4 x EC50 in > 90% of patients. Doses > 200 mg offer little additional increment in proportions achieving target level. Dose, mg QD % > 4 x EC50 % > 6 x EC50 % > 8 x EC50 Predicted Actual Predicted Actual Predicted Actual 62.5 -- 0 -- 0 -- 0 125 70 64 38 43 17 0 175 93 80 58 200 97 88 73 225 98 93 83 250 100 100 97 100 93 100

APeX-2: Phase 3 Trial Design 25 Primary endpoint at Week 24: Rate of Investigator-confirmed HAE attacks through entire treatment period Study powered at >90% to detect a >50% reduction in attack rate over placebo N o 32 BCX7353 150 mg QD* Screening Visit Screening / Run-in Blinded Treatment 24 weeks N o 32 BCX7353 110 mg QD* N o 32 Placebo QD *Doses in Phase 2 APeX-1 were shown as the dihydrochloride salt: 150 mg = 175 mg dihydrochloride salt; 110 mg = 125 mg dihydrochloride salt Final analysis @ week 24

APeX-2: Phase 3 Trial Design – Safety Extension 26 N o 32 BCX7353 150 mg QD* Screening / Run-in Blinded Treatment 24 weeks N o 32 BCX7353 110 mg QD* N o 32 Placebo QD BCX7353 150 mg QD BCX7353 110 mg QD 24 weeks Safety Extension *Doses in Phase 2 APeX-1 were shown as the dihydrochloride salt: 150 mg = 175 mg dihydrochloride salt; 110 mg = 125 mg dihydrochloride salt BCX7353 150 mg QD BCX7353 110 mg QD extension Screening Visit Final analysis @ week 24

APeX-S: Long-term Safety Study Design 27 Endpoints: Long term safety of BCX7353 Durability of response Quality of Life APeX-1 subjects eligible N o 80 BCX7353 150 mg QD 48 Weeks Treatment N o 80 BCX7353 110 mg QD *Doses in Phase 2 APeX-1 were shown as the dihydrochloride salt: 150 mg = 175 mg dihydrochloride salt; 110 mg = 125 mg dihydrochloride salt Analyses as needed for regulatory submissions Safety database: Up to 100 subjects at each dose level Combination of APeX-2 extension and APeX-S

Phase 1/2 Study in Anti-PD-1 Refractory Melanoma 28 Phase 2 Expansion with Ipilimumab Enrolling Dosing: IMO-2125 is given as a single intratumoral agent week 1,2,3,5,8,11,15,19,23 Ipilimumab and pembrolizumab are administered per label beginning week 2 Deep injections are permitted with interventional radiology guidance No need for infectious precautions

Time on Study: Best RECIST v1.1 Response and Largest Percentage Decrease in Target Lesions (8mg subjects) 29

Post-Therapy 08/2016 Pre-Therapy 03/2016 Injected Lesion Distant Lesions Patient 004 Remains a CR since May 2016 30

Phase 1 Conclusions 31 The combination of IMO-2125 with ipilimumab was tolerable at all dose levels studied; Dendritic cell activation, detectable within 24 hours of the first IMO-2125 injection, is evidence for target acquisition at the Recommended Phase 2 Dose (8mg); IMO-2125 with ipilimumab showed clinical activity at the RP2D of 8mg in anti-PD-1 refractory melanoma; 5 of 10 (50%) responded; 7 of 10 (70%) experiencing disease control; and An additional PR of >1year has been reported at 4mg Dose finding for IMO-2125 with pembrolizumab is ongoing, and one partial response (PR) has been seen.

Phase 2 Expansion Update 32 Ipilimumab Combination Phase 2 Trial Expansion – Targeting approximately 60 patients with PD-1 refractory metastatic melanoma treated with 8mg 21 patients enrolled 10 Centers (5 sites currently enrolling) MD Anderson, Roswell Park, Vanderbilt, Huntsman, Uni. of Arizona Open label design Allows for periodic data updates Opportunistic engagements with regulatory authorities

Phase 3 Trial Design 33 Ipilimumab 3 mg/kg Q3wks for 4 doses Ipilimumab (same, beginning wk 2) + intratumoral IMO-2125, wks 1, 2, 3, 5, 8, 11, 16, 20, 24 Unresectable or metastatic melanoma w/ confirmed radiologic progression on or after a PD-1 inhibitor: >21d from most recent aPD-1 and no intervening systemic Tx No prior ipi (except adjuvant) Ocular melanoma excluded 10 endpoint family: OS ORR (RECIST v1.1) No cross-over N~300

Phase 3 Readiness (FPFV 1Q18) 34 Agreement with FDA and MHRA on design and path forward for regular and accelerated approval (one study) Fast Track Designation Granted by U.S. FDA in Q4 2017 Global trial (US, Can, EU, Aus) ~300 patients ~70 sites planned CMC work on track for 1Q18 start Commercial presentation of IMO-2125 will be used Regulatory filings underway Open U.S. IND CTA filings on track

Growth/Partnering Opportunities 35 Expand Transform Unresectable metastatic melanoma High need in anti-PD1-refractory patients Peak year sales estimate > $500 million Emerging I/O addressable tumors “Cold” tumors unaddressable with current I/O Moderate response to cornerstone anti-PD1 Increasing number of approved settings Significant opportunity in tumors with: Low mutation load Low dendritic cell infiltration Bioinformatics research ongoing to identify attractive tumor targets Est. U.S. addressable patient population at 20251 1 Proprietary Idera Commercial Research 2 NSCLC, head and neck, colorectal, bladder and gastric 35 35 Est. U.S. addressable patient population at 20251,2 234,000 Introduce 18,00 0 8,000 1L PD1-refractory 200,0 00 1L PD1-refractory